FOUNDATIONONE®CDx

PATIENT	TUMOR TYPE	REPORT DATE
Chang, Kuang-Yao	Brain gliosarcoma	09 Sep 2022
	COUNTRY CODE	ORDERED TEST #
	TW	ORD-1445637-01

ABOUT THE TEST FoundationOne®CDx is a next-generation sequencing (NGS) based assay that identifies genomic findings within hundreds of cancer-related genes.

PATIENT
DISEASE Brain gliosarcoma
NAME Chang, Kuang-Yao
DATE OF BIRTH 05 September 1973
SEX Male
MEDICAL RECORD # 48757831

PHYSICIAN
ORDERING PHYSICIAN Yeh, Yi-Chen
MEDICAL FACILITY Taipei Veterans General Hospital
ADDITIONAL RECIPIENT None
MEDICAL FACILITY ID 205872
PATHOLOGIST Not Provided

SPECIMEN
SPECIMEN SITE Brain
SPECIMEN ID S111-30418 A (PF22096)
SPECIMEN TYPE Slide Deck
DATE OF COLLECTION 09 August 2022
SPECIMEN RECEIVED 29 August 2022

Biomarker Findings

Microsatellite status - MS-Stable
Tumor Mutational Burden - 0 Muts/Mb

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

CDK4 amplification
MDM2 amplification
PTEN M270fs*28
TERT promoter -124C>T

Report Highlights

- Variants with **diagnostic implications** that may indicate a specific cancer type: ***TERT* promoter -124C>T** (p. 5)
- Evidence-matched **clinical trial options** based on this patient's genomic findings: (p. 6)
- Variants with **prognostic implications** for this tumor type that may impact treatment decisions: ***TERT* promoter -124C>T** (p. 5)

BIOMARKER FINDINGS	THERAPY AND CLINICAL TRIAL IMPLICATIONS
Microsatellite status - MS-Stable	**No therapies or clinical trials.** See Biomarker Findings section
Tumor Mutational Burden - 0 Muts/Mb	**No therapies or clinical trials.** See Biomarker Findings section

GENOMIC FINDINGS	THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)	THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)
***CDK4* -** amplification	none	none
10 Trials see p. 6		
***MDM2* -** amplification	none	none
5 Trials see p. 8		
***PTEN* -** M270fs*28	none	none
10 Trials see p. 9		

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIAL OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

***TERT* -** promoter -124C>T ..... p. 5

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and exhaustive. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies.

Therapies contained in this report may have been approved by the US FDA.

Electronically signed by Erik Williams, M.D. | 09 September 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

BIOMARKER

Microsatellite status

RESULT
MS-Stable

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence, MSS tumors are significantly less likely than MSI-H tumors to respond to anti-PD-1 immune checkpoint inhibitors[1-3], including approved therapies nivolumab and pembrolizumab[4]. In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI-H and experienced a significantly higher ORR compared with non-MSI-H cases (70% vs. 12%, p=0.001)[5].

FREQUENCY & PROGNOSIS

Low-level MSI has been reported in 5-9% of glioblastoma (GBM) samples[6-8]. A large-scale study did not find high-level microsatellite instability (MSI-H) in any of 129 GBM samples[6], although a small-scale study reported MSI-H in 4 of 15 pediatric GBMs and 1 of 12 adult GBMs[9]. The frequency of MSI has been reported to be increased in relapsed compared to primary GBM[6], in GBMs with a previous lower grade astrocytoma[7], and in giant cell GBM compared to classic GBM[8].

FINDING SUMMARY

Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor[10]. Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2[10-12]. This sample is microsatellite-stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers[13-15]. MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins[10,12,14-15].

BIOMARKER

Tumor Mutational Burden

RESULT
0 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1[16-18], anti-PD-1 therapies[16-19], and combination nivolumab and ipilimumab[20-25]. In glioma, a lack of association between TMB and clinical benefit from immune checkpoint inhibitors has been reported[16,26-27]. However, multiple case studies have reported that patients with ultramutated gliomas driven by POLE mutations have benefited from treatment with anti-PD-1[28-29] or anti-PD-L1[30] therapies. Therefore, although increased TMB alone may not be a strong biomarker for PD-1 or PD-L1 inhibitors in this cancer type, these agents may have efficacy for patients with glioma harboring both high TMB and POLE mutation.

FREQUENCY & PROGNOSIS

Gliosarcoma harbors a median TMB of 3.6 mutations per megabase (muts/Mb), and 2% of cases have high TMB (>20 muts/Mb)[31]. For pediatric patients, high TMB has been reported in a subset of high-grade gliomas, frequently in association with mutations in mismatch repair or proofreading genes and in TP53, whereas BRAF alterations or other oncogene fusions were observed more frequently in brain tumors harboring low TMB[32-33]. Increased TMB has been reported to correlate with higher tumor grade in glioma[34] and glioblastoma (GBM) tissue samples with biallelic mismatch repair deficiency (bMMRD)[28], as well as with shorter OS of patients with diffuse glioma[35].

FINDING SUMMARY

Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma[36-37] and cigarette smoke in lung cancer[38-39], treatment with temozolomide-based chemotherapy in glioma[40-41], mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes[42-46], and microsatellite instability (MSI)[42,45-46]. This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors, alone or in combination with other agents[16,26-30].

GENE
CDK4

ALTERATION
amplification

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

CDK4 amplification or activation may predict sensitivity to CDK4/6 inhibitors such as abemaciclib, palbociclib, and ribociclib[47-50]. Clinical benefit has been reported for limited tumor types including patients with CDK4-amplified liposarcoma and sarcoma in response to treatment with abemaciclib[51], palbociclib[47,52], and ribociclib[53].

FREQUENCY & PROGNOSIS

CDK4 amplification has been observed in 9.4% of glioma cases[54]. A study has reported amplification of the 12q14-15 region, where CDK4 and MDM2 reside, in 4.8% (2/42) of glioblastomas[55]. Amplification of CDK4 and corresponding increased CDK4 protein expression has been reported to be associated with a poorer patient outcome in anaplastic astrocytoma and glioblastoma[56-59].

FINDING SUMMARY

CDK4 encodes the cyclin-dependent kinase 4, which regulates the cell cycle, senescence, and apoptosis[60]. CDK4 and its functional homolog CDK6 are activated by D-type cyclins and promote cell cycle progression by inactivating the tumor suppressor Rb[61-62]. Amplification of the chromosomal region that includes CDK4 has been reported in multiple cancer types, including lung cancer, glioblastoma, and liposarcoma, and has been associated with overexpression of CDK4 protein[47,63-69].

GENE
MDM2

ALTERATION
amplification

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

MDM2 antagonists disrupt the MDM2-p53 interaction, thereby stabilizing p53[70]. Preclinical studies have suggested that the amplification of MDM2, in the absence of concurrent TP53 mutations, may increase sensitivity to these agents[71-72]. Preliminary Phase 1 studies of the MDM2-p53 antagonist alrizomadlin (APG-115) reported a PR in a patient with liposarcoma harboring an MDM2 amplification and wildtype for TP53 and SD in 21%–38% (6/28 and 5/13, respectively) of patients in genomically unselected solid tumors[73-74] . A Phase 2 trial of alrizomadlin in combination with pembrolizumab reported a PR in 1 of 3 patients with malignant peripheral nerve sheath tumor that had failed standard therapy, as well as PRs in patients with multiple types of solid tumors that had failed immunotherapy, including 1 out of 14 patients with non-small cell lung cancer; 1 out of 5 patients with urothelial carcinoma; and 2 out of5, 1 out of 5, and 1 out of 11 patients with mucosal, uveal, and cutaneous melanoma, respectively[75]. Phase 1b studies of the MDM2 inhibitor idasanutlin for refractory AML in combination with cytarabine or venetoclax reported anti-leukemic response rates of 33% (25/75) and 37% (11/30), respectively[76-77] ; clinical benefit (58% ORR, 7/12) with idasanutlin monotherapy has been reported for patients with polycythemia vera[78]. The dual MDM2/MDM4 inhibitor ALRN-6924 led to an ORR of 27% (4/15) for patients with TP53 wildtype peripheral T-cell lymphoma in a Phase 2 study[79]; responses have also been observed in TP53 wildtype AML, MDS, Merkel cell carcinoma, colorectal cancer, and liposarcoma[80-81] .

FREQUENCY & PROGNOSIS

MDM2 amplification was reported in 8% (3/38) of gliosarcomas in one study[82]. In the Glioblastoma Multiforme (GBM) TCGA dataset, amplification of MDM2 has been found in 8% of cases[83]. A study has reported amplification of the 12q14-15 region, where MDM2 and CDK4 reside, in 5% (2/42) of GBMs[55]. Amplification of MDM2 has been associated with poor survival in patients with glioblastoma[55,84].

FINDING SUMMARY

MDM2 encodes an E3 ubiquitin protein ligase, which mediates the ubiquitination and subsequent degradation of p53, Rb1, and other proteins[85-87]. MDM2 acts to prevent the activity of the tumor suppressor p53; therefore, overexpression or amplification of MDM2 may be oncogenic[88-89]. Overexpression or amplification of MDM2 is frequent in cancer[90]. Although two retrospective clinical studies suggest that MDM2 amplification may predict a short time-to-treatment failure on anti-PD-1/PD-L1 immune checkpoint inhibitors, with 4/5 patients with MDM2 amplification[91] and 2/3 patients with MDM2 or MDM4 amplification[92] experiencing tumor hyperprogression, amplification of MDM2 or MDM4 was not associated with shorter progression-free survival (PFS) in a retrospective analysis of non-small cell lung cancer (NSCLC) outcomes with immune checkpoint inhibitors (hazard ratio of 1.4, p=0.44)[93]. The latter study reported PFS of >2 months for 5/8 patients with MDM2/MDM4 amplification[93].

GENE
PTEN

ALTERATION
M270fs*28

TRANSCRIPT ID
NM_000314

CODING SEQUENCE EFFECT
808_809insA

VARIANT ALLELE FREQUENCY (% VAF)
29.1%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

PTEN loss or mutation leads to activation of the PI3K-AKT-mTOR pathway and may predict sensitivity to inhibitors of this pathway[94-97]. Across various tissues, most clinical studies have not observed an association between PTEN deficiency and response to inhibitors of the PI3K-AKT-mTOR pathway. However, limited studies in prostate cancer[98-101], renal cell carcinoma[102], breast cancer[103-104], and colorectal cancer[105] have reported an association between PTEN deficiency and response to inhibitors targeting the PI3K-AKT-mTOR pathway. Preclinical data indicate that PTEN loss or inactivation may predict sensitivity to PARP inhibitors[106-110], and clinical benefit has been observed for patients with PTEN-altered breast cancer including triple negative breast cancer[111], ovarian cancer[112], uterine leiomyosarcoma[113], and endometrial cancer[110] treated with PARP inhibitors. However, some studies have reported a lack of association between PTEN mutation and PARP inhibitor sensitivity[114-115].

FREQUENCY & PROGNOSIS

PTEN mutations have been observed in 37% (7/19) to 50% (15/30) of gliosarcomas in small studies[82,116-117]. Studies in the literature have indicated that PTEN alterations (mutation or homozygous deletion) occur most frequently in glioblastoma (GBM), less frequently in anaplastic astrocytoma, and rarely in lower grade glioma subtypes including low grade astrocytoma, oligodendroglioma, oligoastrocytoma, and ependymoma[118-125]. One study detected PTEN mutation in 42% (97/232) and loss in 10% (24/232) of IDH-wildtype GBM samples analyzed[126]. In the TCGA dataset, PTEN mutation was observed in 23% of GBM cases and PTEN deletion was reported in 7% of cases[83], while in the Lower Grade Glioma TCGA dataset, PTEN mutation was observed in 4% of cases and homozygous deletion observed in 1.2% of cases[127]. Loss of PTEN correlated with significantly worse prognosis in all grades of gliomas[122,128].

FINDING SUMMARY

PTEN encodes an inositol phosphatase that functions as a tumor suppressor by negatively regulating the PI3K-AKT-mTOR pathway; loss of PTEN can lead to uncontrolled cell growth and suppression of apoptosis[95]. Alterations such as seen here may disrupt PTEN function or expression[124,129-169].

POTENTIAL GERMLINE IMPLICATIONS

PTEN mutations underlie several inherited disorders, collectively termed PTEN hamartoma tumor syndrome (PHTS), which include Cowden syndrome (CS) and its variant Lhermitte-Duclos disease (LD), Bannayan-Riley-Ruvalcaba syndrome (BRRS), PTEN-related Proteus syndrome (PS), and Proteus-like syndrome[170-171]. The mutation rate for PTEN in these disorders ranges from 20 to 85% of patients[170,172]. The estimated incidence of Cowden syndrome is 1/200,000, which may be an underestimate due to the high variability of this disorder[170]. Given the association between PTEN and these inherited syndromes, in the appropriate clinical context, germline testing for mutations affecting PTEN is recommended.

GENE
TERT

ALTERATION
promoter -124C>T

TRANSCRIPT ID
NM_198253

CODING SEQUENCE EFFECT
-124C>T

VARIANT ALLELE FREQUENCY (% VAF)
21.5%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Therapeutic options for targeting tumors with TERT mutations are limited, although a variety of approaches have been investigated, including immunotherapies using TERT as a tumor-associated antigen and antisense oligonucleotide- or peptide-based therapies. TERT peptide vaccines showed limited anticancer efficacy in clinical trials[173]; however, in one preclinical study, the combination of a TERT peptide vaccine and anti-CTLA-4 therapy suppressed tumor growth[174]. A Phase 2 study of the TERT inhibitor imetelstat for patients with advanced non-small cell lung cancer reported no improvement in PFS or OS[175].

FREQUENCY & PROGNOSIS

TERT promoter mutations have been reported in 51-59% of gliomas[176-177], most frequently in glioblastoma (GBM, 54-84%), gliosarcoma (81%), oligodendroglioma (78%), and historically in oligoastrocytomas (25-31%) but less frequently in lower grade astrocytomas (10-18%) and in only 1% of ependymomas[176-180]. TERT promoter mutation has been shown to be significantly associated with increased TERT gene expression in astrocytoma, oligodendroglioma, and GBM[181]. TERT promoter mutations significantly associate with poor prognosis in patients with GBM, although this correlation may be due to the association with primary GBM as opposed to IDH-positive secondary GBM[176,178,181-182]. In the context of IDH-wildtype glioma, TERT mutations are associated with reduced OS (NCCN CNS Cancers Guidelines, v1.2022).

FINDING SUMMARY

Telomerase reverse transcriptase (TERT, or hTERT) is a catalytic subunit of the telomerase complex, which is required to maintain appropriate chromosomal length[183]. Activation of TERT is a hallmark of cancer, being detected in up to 80-90% of malignancies and absent in quiescent cells[184-186]. Mutations within the promoter region of TERT that confer enhanced TERT promoter activity have been reported in two hotspots, located at -124 bp and -146 bp upstream of the transcriptional start site (also termed C228T and C250T, respectively)[187-189], as well as tandem mutations at positions −124/−125 bp and −138/−139 bp[187].

POTENTIAL DIAGNOSTIC IMPLICATIONS

TERT mutations are associated with 1p/19q co-deletion in oligodendrogliomas, and are highly recurrent in IDH/ATRX-wildtype glioblastoma (GBM) (NCCN CNS Cancers Guidelines, v1.2022)[190].

NOTE Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually updated and should be investigated by the physician or research staff. This is not a comprehensive list of all available clinical trials. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials listed here may have additional enrollment criteria that may require medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see clinicaltrials.gov. Or, visit https://www.foundationmedicine.com/genomic-testing#support-services.

GENE
CDK4

RATIONALE
CDK4 amplification may predict sensitivity to CDK4/6 inhibitors.

ALTERATION
amplification

NCT04282031

PHASE 1/2

A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

TARGETS
CDK6, CDK4, ER, Aromatase

LOCATIONS: Shanghai (China)

NCT03239015

PHASE 2

Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event

TARGETS
EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6

LOCATIONS: Shanghai (China)

NCT02933736

PHASE NULL

Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients

TARGETS
CDK6, CDK4

LOCATIONS: Arizona

NCT04801966

PHASE NULL

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

TARGETS
CDK4, CDK6, PI3K-alpha, PD-L1, MEK, PARP, PD-1, BRAF

LOCATIONS: Melbourne (Australia)

NCT05159245

PHASE 2

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

TARGETS
BRAF, VEGFRs, RET, KIT, ERBB2, TRKB, ALK, TRKC, ROS1, TRKA, SMO, PD-L1, MEK, CDK4, CDK6

LOCATIONS: Kuopio (Finland), Helsinki (Finland), Tampere (Finland), Turku (Finland)

NCT03994796

PHASE 2

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

TARGETS
TRKB, ALK, TRKC, ROS1, TRKA, CDK4, CDK6, PI3K, mTOR

LOCATIONS: Washington, Oregon, Idaho, Montana

NCT04116541

PHASE 2

A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/ Characteristics in Advanced / Metastatic Tumors.

TARGETS
CDK6, CDK4, MDM2, MET, ROS1, RET, VEGFRs

LOCATIONS: Nice (France), Lyon (France), Marseille (France), Toulouse (France), Bordeaux (France)

NCT02981940

PHASE 2

A Study of Abemaciclib in Recurrent Glioblastoma

TARGETS
CDK4, CDK6

LOCATIONS: Utah, California, Massachusetts

NCT05252416

PHASE 1/2

(VELA) Study of BLU-222 in Advanced Solid Tumors

TARGETS
ER, CDK4, CDK6, CDK2

LOCATIONS: Massachusetts, Texas, Florida

NCT02896335

PHASE 2

Palbociclib In Progressive Brain Metastases

TARGETS
CDK4, CDK6

LOCATIONS: Massachusetts

GENE
MDM2

ALTERATION
amplification

RATIONALE
Inhibitors of the MDM2-p53 interaction are being tested in clinical trials. Overexpression or amplification of MDM2 may increase sensitivity to these agents, but more data are required.

NCT04589845

PHASE 2

Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

TARGETS
TRKB, ALK, TRKC, ROS1, TRKA, RET, PD-L1, AKTs, ERBB2, MDM2, PI3K-alpha

LOCATIONS: Taipei City (Taiwan), Taoyuan County (Taiwan), Tainan (Taiwan), Shanghai City (China), Shanghai (China), Shatin (Hong Kong), Hong Kong (Hong Kong), Seoul (Korea, Republic of), Xi'an (China), Tianjin (China)

NCT04785196

PHASE 1/2

APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors

TARGETS
PD-1, MDM2

LOCATIONS: Shanghai (China), Guangzhou (China)

NCT03449381

PHASE 1

This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors)

TARGETS
MDM2

LOCATIONS: Tokyo, Chuo-ku (Japan), Warsaw (Poland), Poznan (Poland), Berlin (Germany), Köln (Germany), Tübingen (Germany), Leuven (Belgium), Barcelona (Spain), California, Ottawa (Canada)

NCT03611868

PHASE 1/2

A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

TARGETS
MDM2, PD-1

LOCATIONS: Brisbane (Australia), South Brisbane (Australia), Bedford Park (Australia), Heidelberg (Australia), California, Arizona, Missouri, Arkansas, Ohio, Pennsylvania

NCT03725436

PHASE 1

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

TARGETS
MDM2, MDM4

LOCATIONS: Texas

GENE
PTEN

ALTERATION
M270fs*28

RATIONALE
PTEN loss or inactivating mutations may lead to increased activation of the PI3K-AKT-mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.

NCT04644068

PHASE 1/2

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

TARGETS
ERBB2, TROP2, PARP

LOCATIONS: Shanghai (China), Seoul (Korea, Republic of), Chongqing (China), Chuo-ku (Japan), Koto-ku (Japan), Melbourne (Australia), Warszawa (Poland), Gdynia (Poland), Grzepnica (Poland), Budapest (Hungary)

NCT04341259

PHASE 1

A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Metastatic Solid Tumors.

TARGETS
AKTs

LOCATIONS: Shanghai City (China)

NCT04337463

PHASE NULL

ATG-008 Combined With Toripalimab in Advanced Solid Tumors

TARGETS
mTORC1, mTORC2, PD-1

LOCATIONS: Chongqing (China), Chengdu (China)

NCT02264678

PHASE 1/2

Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents

TARGETS
ATR, PARP, PD-L1

LOCATIONS: Seongnam-si (Korea, Republic of), Seoul (Korea, Republic of), Goyang-si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom)

NCT04740190

PHASE 2

Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd

TARGETS
PARP

LOCATIONS: Hong Kong (Hong Kong)

NCT04001569

PHASE 1/2

AZD8186 and Paclitaxel in Advanced Gastric Cancer

TARGETS
PI3K-beta

LOCATIONS: Seongnam-si (Korea, Republic of)

NCT05035745

PHASE 1/2

Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

TARGETS
XPO1, PARP

LOCATIONS: Singapore (Singapore)

NCT03772561

PHASE 1

Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies

TARGETS
PARP, AKTs, PD-L1

LOCATIONS: Singapore (Singapore)

NCT05076513

PHASE NULL

Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma

TARGETS
PARP

LOCATIONS: Arizona

NCT04801966

PHASE NULL

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

TARGETS
CDK4, CDK6, PI3K-alpha, PD-L1, MEK, PARP, PD-1, BRAF

LOCATIONS: Melbourne (Australia)

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

APC
V1125A

ARID1A
A162T

CD22
E518K

CDK4
rearrangement

CREBBP
Q278P

MDM2
rearrangement, rearrangement and rearrangement

FoundationOne CDx is designed to include genes known to be somatically altered in human solid tumors that are validated targets for therapy, either approved or in clinical trials, and/or that are unambiguous drivers of oncogenesis based on current knowledge. The current assay interrogates 324 genes as well as introns of 36 genes involved in rearrangements. The assay will be updated periodically to reflect new knowledge about cancer biology.

DNA GENE LIST: ENTIRE CODING SEQUENCE FOR THE DETECTION OF BASE SUBSTITUTIONS, INSERTION/DELETIONS, AND COPY NUMBER ALTERATIONS

ABL1	*ACVR1B*	*AKT1*	*AKT2*	*AKT3*	*ALK*	*ALOX12B*	*AMER1 (FAM123B or WTX)*	
APC	*AR*	*ARAF*	*ARFRP1*	*ARID1A*	*ASXL1*	*ATM*	*ATR*	*ATRX*
AURKA	*AURKB*	*AXIN1*	*AXL*	*BAP1*	*BARD1*	*BCL2*	*BCL2L1*	*BCL2L2*
BCL6	*BCOR*	*BCORL1*	*BRAF*	*BRCA1*	*BRCA2*	*BRD4*	*BRIP1*	*BTG1*
BTG2	*BTK*	*CALR*	*CARD11*	*CASP8*	*CBFB*	*CBL*	*CCND1*	*CCND2*
CCND3	*CCNE1*	*CD22*	*CD274 (PD-L1)*	*CD70*	*CD79A*	*CD79B*	*CDC73*	*CDH1*
CDK12	*CDK4*	*CDK6*	*CDK8*	*CDKN1A*	*CDKN1B*	*CDKN2A*	*CDKN2B*	*CDKN2C*
CEBPA	*CHEK1*	*CHEK2*	*CIC*	*CREBBP*	*CRKL*	*CSF1R*	*CSF3R*	*CTCF*
CTNNA1	*CTNNB1*	*CUL3*	*CUL4A*	*CXCR4*	*CYP17A1*	*DAXX*	*DDR1*	*DDR2*
DIS3	*DNMT3A*	*DOT1L*	*EED*	*EGFR*	*EMSY (C11orf30)*	*EP300*	*EPHA3*	*EPHB1*
EPHB4	*ERBB2*	*ERBB3*	*ERBB4*	*ERCC4*	*ERG*	*ERRFI1*	*ESR1*	*EZH2*
FANCA	*FANCC*	*FANCG*	*FANCL*	*FAS*	*FBXW7*	*FGF10*	*FGF12*	*FGF14*
FGF19	*FGF23*	*FGF3*	*FGF4*	*FGF6*	*FGFR1*	*FGFR2*	*FGFR3*	*FGFR4*
FH	*FLCN*	*FLT1*	*FLT3*	*FOXL2*	*FUBP1*	*GABRA6*	*GATA3*	*GATA4*
GATA6	*GID4 (C17orf39)*	*GNA11*	*GNA13*	*GNAQ*	*GNAS*	*GRM3*	*GSK3B*	*H3-3A (H3F3A)*
HDAC1	*HGF*	*HNF1A*	*HRAS*	*HSD3B1*	*ID3*	*IDH1*	*IDH2*	*IGF1R*
IKBKE	*IKZF1*	*INPP4B*	*IRF2*	*IRF4*	*IRS2*	*JAK1*	*JAK2*	*JAK3*
JUN	*KDM5A*	*KDM5C*	*KDM6A*	*KDR*	*KEAP1*	*KEL*	*KIT*	*KLHL6*
KMT2A (MLL)	*KMT2D (MLL2)*	*KRAS*	*LTK*	*LYN*	*MAF*	*MAP2K1 (MEK1)*	*MAP2K2 (MEK2)*	*MAP2K4*
MAP3K1	*MAP3K13*	*MAPK1*	*MCL1*	*MDM2*	*MDM4*	*MED12*	*MEF2B*	*MEN1*
MERTK	*MET*	*MITF*	*MKNK1*	*MLH1*	*MPL*	*MRE11 (MRE11A)*	*MSH2*	*MSH3*
MSH6	*MST1R*	*MTAP*	*MTOR*	*MUTYH*	*MYC*	*MYCL (MYCL1)*	*MYCN*	*MYD88*
NBN	*NF1*	*NF2*	*NFE2L2*	*NFKBIA*	*NKX2-1*	*NOTCH1*	*NOTCH2*	*NOTCH3*
NPM1	*NRAS*	*NSD2 (WHSC1 or MMSET)*		*NSD3 (WHSC1L1)*	*NT5C2*	*NTRK1*	*NTRK2*	*NTRK3*
P2RY8	*PALB2*	*PARP1*	*PARP2*	*PARP3*	*PAX5*	*PBRM1*	*PDCD1 (PD-1)*	*PDCD1LG2 (PD-L2)*
PDGFRA	*PDGFRB*	*PDK1*	*PIK3C2B*	*PIK3C2G*	*PIK3CA*	*PIK3CB*	*PIK3R1*	*PIM1*
PMS2	*POLD1*	*POLE*	*PPARG*	*PPP2R1A*	*PPP2R2A*	*PRDM1*	*PRKAR1A*	*PRKCI*
PRKN (PARK2)	*PTCH1*	*PTEN*	*PTPN11*	*PTPRO*	*QKI*	*RAC1*	*RAD21*	*RAD51*
RAD51B	*RAD51C*	*RAD51D*	*RAD52*	*RAD54L*	*RAF1*	*RARA*	*RB1*	*RBM10*
REL	*RET*	*RICTOR*	*RNF43*	*ROS1*	*RPTOR*	*SDHA*	*SDHB*	*SDHC*
SDHD	*SETD2*	*SF3B1*	*SGK1*	*SMAD2*	*SMAD4*	*SMARCA4*	*SMARCB1*	*SMO*
SNCAIP	*SOCS1*	*SOX2*	*SOX9*	*SPEN*	*SPOP*	*SRC*	*STAG2*	*STAT3*
STK11	*SUFU*	*SYK*	*TBX3*	*TEK*	*TENT5C (FAM46C)*		*TET2*	*TGFBR2*
TIPARP	*TNFAIP3*	*TNFRSF14*	*TP53*	*TSC1*	*TSC2*	*TYRO3*	*U2AF1*	*VEGFA*
VHL	*WT1*	*XPO1*	*XRCC2*	*ZNF217*	*ZNF703*			

DNA GENE LIST: FOR THE DETECTION OF SELECT REARRANGEMENTS

ALK	*BCL2*	*BCR*	*BRAF*	*BRCA1*	*BRCA2*	*CD74*	*EGFR*	*ETV4*
ETV5	*ETV6*	*EWSR1*	*EZR*	*FGFR1*	*FGFR2*	*FGFR3*	*KIT*	*KMT2A (MLL)*
MSH2	*MYB*	*MYC*	*NOTCH2*	*NTRK1*	*NTRK2*	*NUTM1*	*PDGFRA*	*RAF1*
RARA	*RET*	*ROS1*	*RSPO2*	*SDC4*	*SLC34A2*	*TERC**	*TERT***	*TMPRSS2*

*TERC is an NCRNA

**Promoter region of TERT is interrogated

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Homologous Recombination status
Loss of Heterozygosity (LOH) score
Microsatellite (MS) status
Tumor Mutational Burden (TMB)

FoundationOne CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Cipalstraat 3, 2440 Geel, Belgium. CE

ABOUT FOUNDATIONONE CDX

FoundationOne CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details: www.rochefoundationmedicine.com/f1cdxtech.

INTENDED USE

FoundationOne®CDx (F1CDx) is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI), tumor mutational burden (TMB), and for selected forms of ovarian cancer, loss of heterozygosity (LOH) score, using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with therapies in accordance with approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms.

TEST PRINCIPLE

FoundationOne CDx will be performed exclusively as a laboratory service using DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor samples. The proposed assay will employ a single DNA extraction method from routine FFPE biopsy or surgical resection specimens, 50-1000 ng of which will undergo whole-genome shotgun library construction and hybridization-based capture of all coding exons from 309 cancer-related genes, one promoter region, one non-coding (ncRNA), and select intronic regions from 34 commonly rearranged genes, 21 of which also include the coding exons. The assay therefore includes detection of alterations in a total of 324 genes.

Using an Illumina® HiSeq platform, hybrid capture–selected libraries will be sequenced to high uniform depth (targeting >500X median coverage with >99% of exons at coverage >100X). Sequence data will be processed using a customized analysis pipeline designed to accurately detect all classes of genomic alterations, including base substitutions, indels, focal copy number amplifications, homozygous gene deletions, and selected genomic rearrangements (e.g.,gene fusions). Additionally, genomic signatures including loss of heterozygosity (LOH), microsatellite instability (MSI) and tumor mutational burden (TMB) will be reported.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. The F1CDx report may be used as an aid to inform molecular eligibility for clinical trials. Note: A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

Diagnostic Significance

FoundationOne CDx identifies alterations to select cancer-associated genes or portions of genes (biomarkers). In some cases, the Report also highlights selected negative test results regarding biomarkers of clinical significance.

Qualified Alteration Calls (Equivocal and Subclonal)

An alteration denoted as "amplification – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence that the copy number of a gene exceeds the threshold for identifying copy number amplification. The threshold used in FoundationOne CDx for identifying a copy number amplification is four (4) for *ERBB2* and six (6) for all other genes. Conversely, an alteration denoted as "loss – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence for homozygous deletion of the gene in question. An alteration denoted as "subclonal" is one that the FoundationOne CDx analytical methodology has identified as being present in <10% of the assayed tumor DNA.

Ranking of Therapies and Clinical Trials

Ranking of Therapies in Summary Table

Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

Ranking of Clinical Trials

Pediatric trial qualification → Geographical proximity → Later trial phase.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Limitations

1. In the fractional-based MSI algorithm, a tumor specimen will be categorized as MSI-H, MSS, or MS-Equivocal according to the fraction of microsatellite loci determined to be altered or unstable (i.e., the fraction unstable loci score). In the F1CDx assay, MSI is evaluated based on a genome-wide analysis across >2000 microsatellite loci. For a given microsatellite locus, non-somatic alleles are discarded, and the microsatellite is categorized as unstable if remaining alleles differ from the reference genome. The final fraction unstable loci score is calculated as the number of unstable microsatellite loci divided by the number of evaluable microsatellite loci. The MSI-H and MSS cut-off thresholds were determined by

analytical concordance to a PCR comparator assay using a pan-tumor FFPE tissue sample set. Patients with results categorized as "MS-Stable" with median exon coverage <300X, "MS-Equivocal," or "Cannot Be Determined" should receive confirmatory testing using a validated orthogonal (alternative) method.

2. TMB by F1CDx is determined by counting all synonymous and non-synonymous variants present at 5% allele frequency or greater (after filtering) and the total number is reported as mutations per megabase (mut/Mb) unit. Observed TMB is dependent on characteristics of the specific tumor focus tested for a patient (e.g., primary vs. metastatic, tumor content) and the testing platform used for the detection; therefore, observed TMB results may vary between different specimens for the same patient and between detection methodologies employed on the same sample. The TMB calculation may differ from TMB calculations used by other assays depending on variables such as the amount of genome interrogated, percentage of tumor, assay limit of detection (LoD), filtering of alterations included in the score, and the read depth and other bioinformatic test specifications. Refer to the SSED for a detailed description of these variables in FMI's TMB calculation https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf. The clinical validity of TMB defined by this panel has been established for TMB as a qualitative output for a cut-off of 10 mutations per megabase but has not been established for TMB as a quantitative score.
3. Homologous Recombination status may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas (Coleman et al., 2017; 28916367). Samples with deleterious *BRCA1/2* alteration and/or Loss of Heterozygosity (LOH) score ≥ 16% will be reported as "HRD Positive" and samples with absence of these findings will be reported as "HRD Not Detected," agnostic of potential secondary *BRCA1/2* reversion alterations. Certain potentially deleterious missense or small in-frame deletions in *BRCA1/2* may not be classified as deleterious and, in the absence of an elevated LOH profile, samples with such mutations may be classified as "HRD Not Detected." A result of "HRD Not Detected" does not rule out the presence of a *BRCA1/2* alteration or an elevated LOH profile outside the assay performance characteristic limitations.
4. The LOH score is determined by analyzing SNPs spaced at 1Mb intervals across the genome on the FoundationOne CDx test and extrapolating an LOH profile, excluding arm- and chromosome-wide LOH segments. Detection of LOH has been verified only for ovarian cancer patients, and the LOH score result may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas. The LOH score will be reported as "Cannot Be Determined" if the sample is not of sufficient quality to confidently determine LOH. Performance of the LOH classification has not been established for samples below 35% tumor content. There may be potential interference of ethanol with LOH detection. The interfering effects of xylene, hemoglobin, and triglycerides on the LOH score have not been demonstrated.
5. Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. The test does not provide information about susceptibility.
6. Biopsy may pose a risk to the patient when archival tissue is not available for use with the assay. The patient's physician should determine whether the patient is a candidate for biopsy.
7. Reflex testing to an alternative FDA approved companion diagnostic should be performed for patients who have an *ERBB2* amplification result detected with copy number equal to 4 (baseline ploidy of tumor +2) for confirmatory testing. While this result is considered negative by FoundationOne®CDx (F1CDx), in a clinical concordance study with an FDA approved FISH test, 70% (7 out of 10 samples) were positive, and 30% (3 out of 10 samples) were negative by the FISH test with an average ratio of 2.3. The frequency of *ERBB2* copy number 4 in breast cancer is estimated to be approximately 2%. Multiple references listed in https://www.mycancergenome.org/content/disease/breast-cancer/ERBB2/238/ report the frequency of HER2 overexpression as 20% in breast cancer. Based on the F1CDx HER2 CDx concordance study, approximately 10% of HER2 amplified samples had copy number 4. Thus, total frequency is conservatively estimated to be approximately 2%.

REPORT HIGHLIGHTS

The Report Highlights includes select genomic and therapeutic information with potential impact on patient care and treatment that is specific to the genomics and tumor type of the sample analyzed. This section may highlight information including targeted therapies with potential sensitivity or resistance; evidence-matched clinical trials; and variants with potential diagnostic, prognostic, nontargeted treatment, germline, or clonal hematopoiesis implications. Information included in the Report Highlights is expected to evolve with advances in scientific and clinical research. Findings included in the Report Highlights should be considered in the context of all other information in this report and other relevant patient information. Decisions on patient care and treatment are the responsibility of the treating physician.

VARIANT ALLELE FREQUENCY

Variant Allele Frequency (VAF) represents the fraction of sequencing reads in which the variant is observed. This attribute is not taken into account for therapy inclusion, clinical trial matching, or interpretive content. Caution is recommended in interpreting VAF to indicate the potential germline or somatic origin of an alteration, recognizing that tumor fraction and tumor ploidy of samples may vary.

Precision of VAF for base substitutions and indels

BASE SUBSTITUTIONS	%CV*
Repeatability	5.11 - 10.40
Reproducibility	5.95 - 12.31
INDELS	**%CV***
Repeatability	6.29 - 10.00
Reproducibility	7.33 - 11.71

**Interquartile Range = 1st Quartile to 3rd Quartile*

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >10%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM, BAP1, BRCA1, BRCA2, BRIP1, CHEK2, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, POLE, RAD51C, RAD51D, RET, SDHA, SDHB, SDHC, SDHD, TSC2,* and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's

tumor sequencing is germline or somatic. Interpretation should be based on clinical context.

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1, CBL, DNMT3A, IDH2, JAK2, KMT2D (MLL2), MPL, MYD88, SF3B1, TET2*, and *U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This Report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This Report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne CDx.

TREATMENT DECISIONS ARE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this Test, or the information contained in this Report. Certain sample or variant characteristics may result in reduced sensitivity. FoundationOne CDx is performed using DNA derived from tumor, and as such germline events may not be reported.

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
muts/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

REFERENCE SEQUENCE INFORMATION

Sequence data is mapped to the human genome, Genome Reference Consortium Human Build 37 (GRCh37), also known as hg19.

MR Suite Version (RG) 7.1.0

The median exon coverage for this sample is 787x

1. Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179
2. Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250
3. Lal N, et al. Oncoimmunology (2015) pmid: 25949894
4. Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255
5. Ayers et al., 2016; ASCO-SITC Abstract P60
6. Martinez R, et al. Oncology (2004) pmid: 15331927
7. Martinez R, et al. J. Cancer Res. Clin. Oncol. (2005) pmid: 15672285
8. Martinez R, et al. Cancer Genet. Cytogenet. (2007) pmid: 17498554
9. Szybka M, et al. Clin. Neuropathol. () pmid: 12908754
10. Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942
11. You JF, et al. Br. J. Cancer (2010) pmid: 21081928
12. Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249
13. Boland CR, et al. Cancer Res. (1998) pmid: 9823339
14. Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785
15. Boland CR, et al. Gastroenterology (2010) pmid: 20420947
16. Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254
17. Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386
18. Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947
19. Cristescu R, et al. Science (2018) pmid: 30309915
20. Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829
21. Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845
22. Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128
23. Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394
24. Rozeman EA, et al. Nat Med (2021) pmid: 33558721
25. Sharma P, et al. Cancer Cell (2020) pmid: 32916128
26. Zhao J, et al. Nat. Med. (2019) pmid: 30742119
27. Touat M, et al. Nature (2020) pmid: 32322066
28. Bouffet E, et al. J. Clin. Oncol. (2016) pmid: 27001570
29. Johanns TM, et al. Cancer Discov (2016) pmid: 27683556
30. Lukas RV, et al. J. Neurooncol. (2018) pmid: 30073642
31. Chalmers ZR, et al. Genome Med (2017) pmid: 28420421
32. Patel RR, et al. Pediatr Blood Cancer (2020) pmid: 32386112
33. Johnson A, et al. Oncologist (2017) pmid: 28912153
34. Draaisma K, et al. Acta Neuropathol Commun (2015) pmid: 26699864
35. Wang L, et al. BMC Cancer (2020) pmid: 32164609
36. Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635
37. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803
38. Pfeifer GP, et al. Oncogene (2002) pmid: 12379884
39. Rizvi NA, et al. Science (2015) pmid: 25765070
40. Johnson BE, et al. Science (2014) pmid: 24336570
41. Choi S, et al. Neuro-oncology (2018) pmid: 29452419
42. Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398
43. Briggs S, et al. J. Pathol. (2013) pmid: 23447401
44. Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393
45. Nature (2012) pmid: 22810696
46. Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919
47. Dickson MA, et al. J. Clin. Oncol. (2013) pmid: 23569312
48. Flaherty KT, et al. Clin. Cancer Res. (2012) pmid: 22090362
49. Patnaik A, et al. Cancer Discov (2016) pmid: 27217383
50. Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767
51. Dickson et al., 2019; ASCO Abstract 11004
52. Dickson MA, et al. JAMA Oncol (2016) pmid: 27124835
53. Peguero et al., 2016; ASCO Abstract 2528
54. Jonsson P, et al. Clin. Cancer Res. (2019) pmid: 31263031
55. Zheng S, et al. Genes Dev. (2013) pmid: 23796897
56. Kim H, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20080666
57. Ruano Y, et al. Am. J. Clin. Pathol. (2009) pmid: 19141386
58. Fischer U, et al. Mol. Cancer Res. (2008) pmid: 18403636
59. Bäcklund LM, et al. Br. J. Cancer (2005) pmid: 15970925
60. Choi YJ, et al. Oncogene (2014) pmid: 23644662
61. Cell (1995) pmid: 7736585
62. Musgrove EA, et al. Nat. Rev. Cancer (2011) pmid: 21734724
63. Wikman H, et al. Genes Chromosomes Cancer (2005) pmid: 15543620
64. Rao SK, et al. J. Neurooncol. (2010) pmid: 19609742
65. Chung L, et al. Am. J. Surg. Pathol. (2009) pmid: 19574885
66. Ragazzini P, et al. Histol. Histopathol. (2004) pmid: 15024701
67. Dujardin F, et al. Mod. Pathol. (2011) pmid: 21336260
68. Zhang K, et al. Cancer Res. (2013) pmid: 23393200
69. Horvai AE, et al. Mod. Pathol. (2009) pmid: 19734852
70. Cheok CF, et al. Nat Rev Clin Oncol (2011) pmid: 20975744
71. Ohnstad HO, et al. Cancer (2013) pmid: 23165797
72. Gamble LD, et al. Oncogene (2012) pmid: 21725357
73. Zhang et al., 2019; ASCO Abstract 3124
74. Rasco et al., 2019; ASCO Abstract 3126
75. Tolcher et al., 2021; ASCO Abstract 2506
76. Martinelli et al., 2016; EHA21 Abstract S504
77. Daver et al., 2018; ASH Abstract 767
78. Mascarenhas et al., 2019; ASH Abstract 134
79. Shustov et al., 2018; ASH Abstract 1623
80. Sallman et al., 2018; ASH Abstract 4066
81. Meric-Bernstam et al., 2017; ASCO Abstract 2505
82. Actor B, et al. Genes Chromosomes Cancer (2002) pmid: 12112531
83. Brennan CW, et al. Cell (2013) pmid: 24120142
84. Fischer U, et al. Int. J. Cancer (2010) pmid: 19839052
85. Sdek P, et al. Mol. Cell (2005) pmid: 16337594
86. Brady M, et al. Mol. Cell. Biol. (2005) pmid: 15632057
87. Li M, et al. Mol. Cell (2004) pmid: 15053880
88. Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675
89. Cordon-Cardo C, et al. Cancer Res. (1994) pmid: 8306343
90. Beroukhim R, et al. Nature (2010) pmid: 20164920
91. Kato S, et al. Clin. Cancer Res. (2017) pmid: 28351930
92. Singavi et al., 2017; ESMO Abstract 1140PD
93. Rizvi H, et al. J. Clin. Oncol. (2018) pmid: 29337640
94. Courtney KD, et al. J. Clin. Oncol. (2010) pmid: 20085938
95. Simpson L, et al. Exp. Cell Res. (2001) pmid: 11237521
96. Patnaik A, et al. Ann. Oncol. (2016) pmid: 27672108
97. Milella M, et al. Sci Rep (2017) pmid: 28220839
98. Templeton AJ, et al. Eur. Urol. (2013) pmid: 23582881
99. Sweeney C, et al. Lancet (2021) pmid: 34246347
100. de Bono JS, et al. Clin. Cancer Res. (2019) pmid: 30037818
101. Saura C, et al. Cancer Discov (2017) pmid: 27872130
102. Voss MH, et al. Clin. Cancer Res. (2018) pmid: 30327302
103. André F, et al. J. Clin. Oncol. (2016) pmid: 27091708
104. Schmid P, et al. J. Clin. Oncol. (2019) pmid: 31841354
105. Weldon Gilcrease G, et al. Invest New Drugs (2019) pmid: 30302599
106. Mendes-Pereira AM, et al. EMBO Mol Med (2009) pmid: 20049735
107. Shen Y, et al. Clin. Cancer Res. (2013) pmid: 23881923
108. Chatterjee P, et al. PLoS ONE (2013) pmid: 23565244
109. McCormick A, et al. Int. J. Gynecol. Cancer (2016) pmid: 26905328
110. Forster MD, et al. Nat Rev Clin Oncol (2011) pmid: 21468130
111. Eikesdal HP, et al. Ann Oncol (2021) pmid: 33242536
112. Dougherty et al., 2014; ASCO Abstract 5536
113. Pan M, et al. Perm J (2021) pmid: 33970096
114. Sandhu SK, et al. Lancet Oncol. (2013) pmid: 23810788
115. Romero I, et al. Gynecol Oncol (2020) pmid: 32988624
116. Reis RM, et al. Am. J. Pathol. (2000) pmid: 10666371
117. Zaki MM, et al. Sci Rep (2021) pmid: 34504233
118. Zhou XP, et al. Int. J. Cancer (1999) pmid: 10096247
119. Rasheed BK, et al. Cancer Res. (1997) pmid: 9331072
120. Davies MP, et al. Br. J. Cancer (1999) pmid: 10188904
121. Smith JS, et al. J. Natl. Cancer Inst. (2001) pmid: 11504770
122. Lin H, et al. Clin. Cancer Res. (1998) pmid: 9796977
123. Schmidt EE, et al. J. Neuropathol. Exp. Neurol. (1999) pmid: 10560660
124. Kato H, et al. Clin. Cancer Res. (2000) pmid: 11051241
125. Furnari FB, et al. Genes Dev. (2007) pmid: 17974913
126. Yan et al. 2020; DOI:10.1200/PO.19.00385
127. Cancer Genome Atlas Research Network, et al. N. Engl. J. Med. (2015) pmid: 26061751
128. Srividya MR, et al. Neuropathology (2011) pmid: 21134002
129. Campbell RB, et al. J. Biol. Chem. (2003) pmid: 12857747
130. Rodríguez-Escudero I, et al. Hum. Mol. Genet. (2011) pmid: 21828076
131. He X, et al. Cancer Res. (2013) pmid: 23475934
132. Han SY, et al. Cancer Res. (2000) pmid: 10866302
133. Myers MP, et al. Proc. Natl. Acad. Sci. U.S.A. (1998) pmid: 9811831
134. Pradella LM, et al. BMC Cancer (2014) pmid: 24498881
135. Kim JS, et al. Mol. Cell. Biol. (2011) pmid: 21536651
136. Denning G, et al. Oncogene (2007) pmid: 17213812
137. Hlobilkova A, et al. Anticancer Res. () pmid: 16619501
138. Redfern RE, et al. Protein Sci. (2010) pmid: 20718038
139. Shenoy S, et al. PLoS ONE (2012) pmid: 22505997
140. Wang Y, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19329485
141. Okumura K, et al. J. Biol. Chem. (2006) pmid: 16829519
142. Lee JO, et al. Cell (1999) pmid: 10555148
143. Maxwell GL, et al. Cancer Res. (1998) pmid: 9635567
144. Risinger JI, et al. Clin. Cancer Res. (1998) pmid: 9865913
145. Fenton TR, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22891331
146. Ngeow J, et al. J. Clin. Endocrinol. Metab. (2012) pmid: 23066114
147. Lobo GP, et al. Hum. Mol. Genet. (2009) pmid: 19457929
148. Liu J, et al. Oncogene (2014) pmid: 23995781
149. Maehama T, et al. Annu. Rev. Biochem. (2001) pmid: 11395408
150. De Vivo I, et al. J. Med. Genet. (2000) pmid: 10807691

151. Ramaswamy S, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10051603
152. Liu JL, et al. Mol. Cell. Biol. (2005) pmid: 15988030
153. Karoui M, et al. Br. J. Cancer (2004) pmid: 15026806
154. Gil A, et al. PLoS ONE (2015) pmid: 25875300
155. Furnari FB, et al. Cancer Res. (1998) pmid: 9823298
156. Spinelli L, et al. J. Med. Genet. (2015) pmid: 25527629
157. Mingo J, et al. Eur. J. Hum. Genet. (2018) pmid: 29706633
158. Wang Q, et al. J. Mol. Graph. Model. (2010) pmid: 20538496
159. Andrés-Pons A, et al. Cancer Res. (2007) pmid: 17942903
160. Butler MG, et al. J. Med. Genet. (2005) pmid: 15805158
161. Georgescu MM, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10468583
162. Staal FJ, et al. Br. J. Cancer (2002) pmid: 12085208
163. Nguyen HN, et al. Oncogene (2014) pmid: 24292679
164. Rahdar M, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19114656
165. Das S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12808147
166. Wang X, et al. Biochem. J. (2008) pmid: 18498243
167. Valiente M, et al. J. Biol. Chem. (2005) pmid: 15951562
168. Nguyen HN, et al. Oncogene (2015) pmid: 25263454
169. Shan L, et al. Cell Discov (2020) pmid: 32704382
170. Blumenthal GM, et al. Eur. J. Hum. Genet. (2008) pmid: 18781191
171. Orloff MS, et al. Oncogene (2008) pmid: 18794875
172. Zbuk KM, et al. Nat. Rev. Cancer (2007) pmid: 17167516
173. Nat Rev Clin Oncol (2017) pmid: 27245281
174. Duperret EK, et al. Mol Ther (2018) pmid: 29249395
175. Chiappori AA, et al. Ann Oncol (2015) pmid: 25467017
176. Killela PJ, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 23530248
177. Killela PJ, et al. Oncotarget (2014) pmid: 24722048
178. Nonoguchi N, et al. Acta Neuropathol. (2013) pmid: 23955565
179. Liu X, et al. Cell Cycle (2013) pmid: 23603989
180. Koelsche C, et al. Acta Neuropathol. (2013) pmid: 24154961
181. Arita H, et al. Acta Neuropathol. (2013) pmid: 23764841
182. Reitman ZJ, et al. Acta Neuropathol. (2013) pmid: 24217890
183. Shay JW, et al. Semin. Cancer Biol. (2011) pmid: 22015685
184. Shay JW, et al. Eur. J. Cancer (1997) pmid: 9282118
185. Kim NW, et al. Science (1994) pmid: 7605428
186. Hanahan D, et al. Cell (2000) pmid: 10647931
187. Horn S, et al. Science (2013) pmid: 23348503
188. Huang FW, et al. Science (2013) pmid: 23348506
189. Vinagre J, et al. Nat Commun (2013) pmid: 23887589
190. Weller M, et al. Nat Rev Clin Oncol (2021) pmid: 33293629